candesartan has been researched along with Anemia in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Meara, E | 1 |
| Clayton, T | 1 |
| McEntegart, MB | 1 |
| McMurray, JJ | 1 |
| Lang, CC | 1 |
| Roger, SD | 1 |
| Young, JB | 1 |
| Solomon, SD | 1 |
| Granger, CB | 1 |
| Ostergren, J | 1 |
| Olofsson, B | 1 |
| Michelson, EL | 1 |
| Pocock, S | 1 |
| Yusuf, S | 1 |
| Swedberg, K | 1 |
| Pfeffer, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anemia in Chronic Heart Failure: Etiology, Comparisons With Renal Disease, and Relationships With Biomarkers and Left Ventricular Remodeling.[NCT00834691] | 180 participants (Anticipated) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for candesartan and Anemia
| Article | Year |
|---|---|
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Topics: Aged; Anemia; Benzimidazoles; Biphenyl Compounds; Female; Glomerular Filtration Rate; Heart Failure; | 2006 |